![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Oxford to Resume Global Trial of Hydroxychloroquine to Prevent COVID-19
Oxford to Resume Global Trial of Hydroxychloroquine to Prevent COVID-19
![hydroxychloroquine pill bottle](https://www.fdanews.com/ext/resources/test/Drug-Images4/hydroxychloroquine-pill-bottle.gif?t=1585602653&width=430)
The University of Oxford is resuming recruitment for its global clinical trial of hydroxychloroquine and chloroquine for possible prevention of COVID-19 infections.
The large-scale trial, which aims to enroll 40,000 healthcare workers, was paused after a now-retracted study found the antimalarial drugs had no benefit as a treatment for COVID-19 patients. The findings of the retracted study were based on suspect data so UK regulators have told Oxford they can resume the study of the drug for the prevention of COVID-19.
The UK arm of the trial will resume recruitment this week, and new sites are being established in Thailand and Southeast Asia, Africa and South America.
Upcoming Events
-
21Oct